Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients
Status PubMed-not-MEDLINE Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
24327932
PubMed Central
PMC3850022
DOI
10.4161/onci.25619
PII: 2013ONCOIMM0166
Knihovny.cz E-zdroje
- Klíčová slova
- FoxP3, T regulatory cells, disease progression, immune suppression, multiple myeloma, suppressor cells,
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Multiple myeloma (MM) patients exhibit consistent degrees of immune dysfunction. Regulatory T cells contribute to the establishment of an immunosuppressive status in MM patients, hence favoring disease progression.
Zobrazit více v PubMed
Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3–9. doi: 10.1038/leu.2008.291. PubMed DOI PMC
Muthu Raja KR, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One. 2012;7:e47077. doi: 10.1371/journal.pone.0047077. PubMed DOI PMC
Feyler S, Scott GB, Parrish C, Jarmin S, Evans P, Short M, et al. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One. 2012;7:e35981. doi: 10.1371/journal.pone.0035981. PubMed DOI PMC
Tang XL, Smith TR, Kumar V. Specific control of immunity by regulatory CD8 T cells. Cell Mol Immunol. 2005;2:11–9. PubMed
Muthu Raja KR, Kubiczkova L, Rihova L, Piskacek M, Vsianska P, Hezova R, et al. Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment. PLoS One. 2012;7:e49446. doi: 10.1371/journal.pone.0049446. PubMed DOI PMC
Muthu Raja KR, Kovarova L, Hajek R. Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leuk Lymphoma. 2012;53:1406–8. doi: 10.3109/10428194.2011.652106. PubMed DOI
Muthu Raja KR, Plasil M, Rihova L, Pelcova J, Adam Z, Hájek R. Flow cytometry based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment. Cytometry Part B: Clinical Cytometry. 2013 doi: 10.1002/cytob.21109. Forthcoming. PubMed DOI
Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets. 2010;10:155–67. doi: 10.2174/156800910791054239. PubMed DOI
Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood. 2011;117:1605–13. doi: 10.1182/blood-2010-04-278432. PubMed DOI
